Showing results (811-820 of 1,794) with videos related to
Sort By:
Pageof 180
Mabs|March 13, 2024
Do antibody CDR loops change conformation upon binding?Chu'nan Liu, Lilian M Denzler, Oliver E C Hood, et al.Mabs|March 18, 2024
Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfacesW van der Wulp, W Luu, M E Ressing, et al.Mabs|July 1, 2024
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four erasBrian KelleyMabs|July 23, 2024
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapyPatrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, et al.Mabs|February 9, 2024
Electrostatic properties of human germlines and biodistribution of small biologicsLeticia Maria De Souza Cordeiro, Kelley Christine Atkinson, Argin Aivazian, et al.Mabs|January 19, 2024
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitroOmar S Qureshi, Emma J Sutton, Rosemary F Bithell, et al.Mabs|October 4, 2024
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructsItzel Condado-Morales, Fabian Dingfelder, Isabel Waibel, et al.Mabs|September 26, 2024
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaquesJoanna Zikos, Gabriela M Webb, Helen L Wu, et al.Mabs|August 8, 2024
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancerXiaojie Chu, Seungmin Shin, Du-San Baek, et al.Mabs|May 14, 2025
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseasesTao Yin, Aubin Ramon, Matthew Greenig, et al.Pageof 180